CD274 and neoplasm: Although detection of tumour and/or immune cell PD-L1 by immunohistochemistry or tumour mutation burden (TMB) has been investigated as a potential biomarker for response to ICIs, the prediction value has not been determined, and conflicting results have been reported [5].